Information Provided By:
Fly News Breaks for November 7, 2019
Nov 7, 2019 | 09:26 EDT
RBC Capital analyst Kennen MacKay lowered his price target on Puma Biotechnology to $13 and kept his Sector Perform rating after its Q3 results showed a miss on Nerlynx sales. The analyst warns that the print may reflect lower demand due to dose-reductions, also noting his lowered estimates in late-stage metastatic breast cancer where he sees greater competitive pressure from other HER2+ agents in that setting.
News For PBYI From the Last 2 Days
There are no results for your query PBYI